✕

Markets

Insider Trading

Hedge Funds

Retirement

Opinion

Intellia Therapeutics (NTLA) Emerges as a Bright Spot Amid Tech Selloff

Intellia Therapeutics Inc. (NASDAQ:NTLA) is one of the 10 Stocks With Monster Gains Amid Market Turmoil.

Intellia Therapeutics snapped a three-day losing streak on Friday, jumping 5.04 percent to finish at $10 apiece, as investor funds fled technology stocks to lower-risk assets to mitigate risks from ongoing AI concerns. Week-on-week, the stock grew 3 percent.

The rally can be supported by portfolio positioning on optimism for Lonvo-z’s approval by the Food and Drug Administration for the treatment of hereditary angioedema, with Intellia Therapeutics Inc. noting that the agency has so far not requested unusual information regarding the therapy candidate.

For illustration purposes only. Photo by Gustavo Fring on Pexels

The FDA set a deadline of March 10, 2027, for its decision on the listed firm’s biologics license application.

Additionally, it said that the FDA advised that it is not currently planning to hold an advisory committee to discuss the application.

If approved, Lonvo-z would become the world’s first in vivo CRISPR-based therapy and the only one-time treatment for HAE.

Lonvo-z aside, Intellia Therapeutics Inc. reported a 25.8 percent higher net loss of $127.48 million in the third quarter of the year, versus $101 million in the same period last year. It has yet to earn any revenue.

Total operating expenses increased by 3.4 percent to $129.49 million from $125.2 million year-on-year.

READ NEXT: 10 Best US Stocks to Buy Under $25 and Bruce Berkowitz’s 10 Biggest Stock Bets for 2027

Follow Insider Monkey on Google News.